Literature DB >> 21718807

Antibodies against acute phase proteins and their functions in the pathogenesis of disease: a collective profile of 25 different antibodies.

Katja Lakota1, Polona Zigon, Katjusa Mrak-Poljsak, Blaz Rozman, Yehuda Shoenfeld, Snezna Sodin-Semrl.   

Abstract

The acute phase response is a defense system in which the innate immune response is activated following injury or infection. Positive and negative acute phase proteins (APPs) are crucial for protecting the host organism, as well as returning it to homeostatic levels, the first with elevated concentrations and the latter with decreased concentrations during the acute phase. Reports about the presence of antibodies against APPs are known, however their individual, as well as potentially collective, pathological or physiological roles are still emerging. Some of these autoantibodies are specifically connected with diseases (such as pancreatic secretory trypsin inhibitor and C3, C4 nephritic factors), while others have been reported as natural antibodies. The persistent presence (even if only minor) of autoantibodies in healthy blood donors indicates an overlapping category of autoantibodies, which could become pathogenic, depending on the autoantibody characteristics such as avidity, epitope specificity, changes in the microenvironment leading to different oxidative status and others. This review uses the novel approach of studying the overall autoantibody population against APPs, their functions and connections to diseases. The primary function of autoantibodies against APPs (anti-APPs) is thought to promote their clearance, however autoantibodies against negative APPs have also been found and applying the same role to those is doubtful. There is also the theory of consumption in the stage of inflammation, which could be relevant to anti-APPs. Reports about protective roles of autoantibodies are also emerging, showing lowered levels of antibodies in diseases, which could be interesting for therapeutic intervention.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21718807     DOI: 10.1016/j.autrev.2011.06.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  5 in total

1.  Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer.

Authors:  Carolina Panis; Luciana Pizzatti; Aedra Carla Bufalo; Ana Cristina Herrera; Vanessa Jacob Victorino; Rubens Cecchini; Eliana Abdelhay
Journal:  Tumour Biol       Date:  2015-10-15

Review 2.  Manufactured and airborne nanoparticle cardiopulmonary interactions: a review of mechanisms and the possible contribution of mast cells.

Authors:  Jonathan H Shannahan; Urmila P Kodavanti; Jared M Brown
Journal:  Inhal Toxicol       Date:  2012-04       Impact factor: 2.724

3.  Serum Amyloid A Stimulates PKR Expression and HMGB1 Release Possibly through TLR4/RAGE Receptors.

Authors:  Wei Li; Shu Zhu; Jianhua Li; Jason D'Amore; John D'Angelo; Huan Yang; Ping Wang; Kevin J Tracey; Haichao Wang
Journal:  Mol Med       Date:  2015-06-02       Impact factor: 6.354

4.  The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors.

Authors:  Shinta Oktya Wardhani; Jonny Karunia Fajar; Nina Nurarifah; Djoko Heri Hermanto; Siti Fatonah; Susanthy Djajalaksana; Arie Zainul Fatoni; Putu Moda Arsana; Laksmi Wulandari; Gatot Soegiarto; Kuldeep Dhama; Harapan Harapan
Journal:  Clin Epidemiol Glob Health       Date:  2021-05-10

5.  Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells.

Authors:  Tadeja Kuret; Katja Lakota; Polonca Mali; Saša Čučnik; Sonja Praprotnik; Matija Tomšič; Snezna Sodin-Semrl
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.